 Several anti @-@ angiogenesis drugs approved for other conditions , such as cancer , have been investigated in small clinical trials . The anti @-@ <unk> antibody bevacizumab , for instance , has been used off @-@ label in several studies . In the largest study conducted so far , bevacizumab infusion was associated with a decrease in cardiac output and reduced duration and number of episodes of epistaxis in treated HHT patients . Thalidomide , another anti @-@ angiogenesis drug , was also reported to have beneficial effects in HHT patients . Thalidomide treatment was found to induce vessel maturation in an experimental mouse model of HHT and to reduce the severity and frequency of nosebleeds in the majority of a small group of HHT patients . The blood hemoglobin levels of these treated patients rose as a result of reduced hemorrhage and enhanced blood vessel stabilization . 
